Patents by Inventor Tom Tong Lee

Tom Tong Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF
    Publication number: 20240131156
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from the differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: October 18, 2020
    Publication date: April 25, 2024
    Inventors: Bahram VALAMEHR, Ryan BJORDAHL, Tom Tong LEE, Jode GOODRIDGE
  • ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF
    Publication number: 20240115602
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from the differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: October 7, 2020
    Publication date: April 11, 2024
    Inventors: Bahram VALAMEHR, Ryan BJORDAHL, Tom Tong LEE, Jode GOODRIDGE
  • CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING
    Publication number: 20240002532
    Abstract: Provided are chimeric antigen receptors (CAR) specific to a selected tumor antigen. Also provided are structure designs and function profiles of provided CAR candidates.
    Type: Application
    Filed: June 30, 2023
    Publication date: January 4, 2024
    Inventors: Bahram VALAMEHR, Tom Tong LEE, Martin HOSKING, Susumu YAMAMOTO, Tatsuo MAEDA
  • ENGINEERED IPSC AND IMMUNE EFFECTOR CELLS FOR HETEROGENOUS TUMOR CONTROL
    Publication number: 20230405121
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The iPSC-derived effector cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: November 4, 2021
    Publication date: December 21, 2023
    Inventors: Bahram VALAMEHR, Martin HOSKING, Tom Tong LEE, John Charles GOULDING
  • CELLS HAVING SOLID TUMOR TARGETING BACKBONE AND USE THEREOF
    Publication number: 20230357716
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional genome editing that delivers improved or enhanced therapeutic effects. Further provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: June 30, 2023
    Publication date: November 9, 2023
    Inventors: Bahram VALAMEHR, Tom Tong LEE, Martin HOSKING, Eigen PERALTA, Chia-Wei CHANG
  • MULTI-TARGETING EFFECTOR CELLS AND USE THEREOF
    Publication number: 20220378831
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: September 25, 2020
    Publication date: December 1, 2022
    Inventors: Bahram VALAMEHR, Ryan BJORDAHL, Jode GOODRIDGE, Tom Tong LEE
  • IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF
    Publication number: 20220275333
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: July 17, 2020
    Publication date: September 1, 2022
    Inventors: Bahram VALAMEHR, Tom Tong LEE, Ryan BJORDAHL, Jode GOODRIDGE
  • Enhanced immune effector cells and use thereof
    Patent number: 11365394
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: June 21, 2022
    Assignee: Fate Therapeutics, Inc.
    Inventors: Bahram Valamehr, Ryan Bjordahl, Jode Goodridge, Tom Tong Lee
  • CD3 RECONSTITUTION IN ENGINEERED iPSC AND IMMUNE EFFECTOR CELLS
    Publication number: 20220184142
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The iPSC-derived cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: April 8, 2020
    Publication date: June 16, 2022
    Inventors: Bahram VALAMEHR, Tom Tong LEE, Alec WITTY, Mochtar PRIBADI
  • Genomic engineering of pluripotent cells
    Patent number: 11352607
    Abstract: Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: June 7, 2022
    Assignee: Fate Therapeutics, Inc.
    Inventors: Bahram Valamehr, Ramzey Abujarour, Tom Tong Lee, Weijie Lan, Raedun Clarke, Ryan Bjordahl
  • IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
    Publication number: 20220127328
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: November 25, 2019
    Publication date: April 28, 2022
    Inventors: Bahram VALAMEHR, Ryan BJORDAHL, Tom Tong LEE
  • GENOMIC ENGINEERING OF PLURIPOTENT CELLS
    Publication number: 20210324340
    Abstract: Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.
    Type: Application
    Filed: April 22, 2021
    Publication date: October 21, 2021
    Inventors: Bahram VALAMEHR, Ramzey ABUJAROUR, Tom Tong LEE, Weijie LAN, Raedun CLARKE, Ryan BJORDAHL
  • Genomic engineering of pluripotent cells
    Patent number: 11072781
    Abstract: Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: July 27, 2021
    Assignee: FATE THERAPEUTICS, INC.
    Inventors: Bahram Valamehr, Ramzey Abujarour, Tom Tong Lee, Weijie Lan, Raedun Clarke, Ryan Bjordahl
  • ENHANCED IMMUNE EFFECTOR CELLS AND USE THEREOF
    Publication number: 20210180017
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: February 19, 2021
    Publication date: June 17, 2021
    Inventors: Bahram VALAMEHR, Ryan BJORDAHL, Jode GOODRIDGE, Tom Tong LEE
  • IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF
    Publication number: 20210163622
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: January 29, 2021
    Publication date: June 3, 2021
    Inventors: Bahram VALAMEHR, Tom Tong LEE, Ryan BJORDAHL, Jode GOODRIDGE
  • ENHANCED IMMUNE EFFECTOR CELLS AND USE THEREOF
    Publication number: 20210163895
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: January 11, 2021
    Publication date: June 3, 2021
    Inventors: Bahram VALAMEHR, Ryan BJORDAHL, Jode GOODRIDGE, Tom Tong LEE
  • ENHANCED IMMUNE EFFECTOR CELLS AND USE THEREOF
    Publication number: 20210087537
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: December 21, 2018
    Publication date: March 25, 2021
    Inventors: Bahram VALAMEHR, Ryan BJORDAHL, Jode GOODRIDGE, Tom Tong LEE
  • Enhanced immune effector cells and use thereof
    Patent number: 10927346
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: February 23, 2021
    Assignee: FATE THERAPEUTICS, INC.
    Inventors: Bahram Valamehr, Ryan Bjordahl, Jode Goodridge, Tom Tong Lee
  • ENGINEERED IMMUNE EFFECTOR CELLS AND USE THEREOF
    Publication number: 20210024959
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: March 28, 2019
    Publication date: January 28, 2021
    Inventors: Bahram VALAMEHR, Ryan BJORDAHL, Jode GOODRIDGE, Tom Tong LEE
  • IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
    Publication number: 20210015859
    Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
    Type: Application
    Filed: November 30, 2018
    Publication date: January 21, 2021
    Inventors: Bahram VALAMEHR, Ryan BJORDAHL, Tom Tong LEE, Svetlana GAIDAROVA